This post was originally published on this site People with high exposure to sunlight or ultraviolet radiation are significantly less likely to develop non-Hodgkin’s lymphoma compared to those with low exposure, but vitamin D levels in the body have no impact on disease incidence, a new study shows. The study, “Vitamin D status and risk…

This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended that Lynparza (olaparib) be approved as a first-line maintenance therapy for women with BRCA-mutated advanced ovarian cancer, AstraZeneca and Merck announced. Specifically, the recommendation is for women who are responding, partially or completely,…

This post was originally published on this site ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and anti-tumor activity after large-scale manufacturing, a study says. The preclinical findings were reported in the study, “Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA…

This post was originally published on this site Gritstone Oncology is advancing its investigational immunotherapy Slate into Phase 1 clinical studies sooner than planned, and expects patient enrollment to start as early as mid-2019, the company announced. This follows feedback from the U.S. Food and Drug Administration (FDA), which will review toxicity data from Granite…

This post was originally published on this site Recent immunosuppression, which causes a drop in CD4 T-cell levels, and prolonged exposure to high HIV viral load are two independent predictors of non-Hodgkin’s lymphoma among people living with HIV, a recent study shows. While these two measures also predicted the risk of diffuse large B-cell lymphoma (DLBCL)…

This post was originally published on this site Combining radiation therapy with immune checkpoint inhibitors induces an immune response to both irradiated and non-irradiated glioblastoma, a study in mice found, suggesting that a combination of these approaches could improve survival outcomes for those patients. The findings were presented recently at the 2019 American Association of…

This post was originally published on this site Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) seeking the approval of its androgen receptor inhibitor Erleada (apalutamide) for patients with metastatic castration-sensitive prostate cancer (CSPC). The supplemental new drug application is based on data from the ongoing Phase 3 TITAN clinical trial…

This post was originally published on this site Too few women with ovarian cancer and breast cancer are getting the recommended genetic tests that help evaluate their risk of developing other cancers – which could guide changes in their clinical care – according to a population-based study done in California and Georgia. The discrepancy is…

This post was originally published on this site A triple regimen composed of Kyprolis (carfilzomib), thalidomide, and dexamethasone, given before and after high-dose chemotherapy and autologous stem cell transplant, is safe and highly effective for the treatment of newly diagnosed multiple myeloma, results of a Phase 2 clinical trial show. The study, “Phase 2 Study…

This post was originally published on this site Since her diagnosis of metastatic breast cancer two years ago, Karen Peterson has been amid a whirlwind of medical appointments and healthcare professionals. It’s often overwhelming. “Managing it all is like a job,” the 54-year-old New York City resident said in an interview with Breast Cancer News.…

This post was originally published on this site A new imaging-guided surgical technique that makes ovarian cancer tumors glow under near-infrared light can help surgeons remove tumors as small as 0.3 millimeters, a study in mice shows. The approach also increased mice’s lifespan by 40% compared to mice treated with standard non-imaging-guided surgery. Researchers are…

This post was originally published on this site Forty Seven and Genentech are extending their agreement to include a third clinical trial evaluating a combination of the investigational 5F9 plus Rituxan (rituximab) and Tecentriq (atezolizumab) in patients with diffuse large B-cell lymphoma (DLBCL). The decision builds on prior Phase 1b data, where a combination of 5F9 and Rituxan was safe and eliminated tumors in one-third of DLBCL patients…